[go: up one dir, main page]

WO2025008409A3 - Substituted 2-phenylpiperidine compounds for use in the diagnosis, treatment and/or prevention of cancer - Google Patents

Substituted 2-phenylpiperidine compounds for use in the diagnosis, treatment and/or prevention of cancer Download PDF

Info

Publication number
WO2025008409A3
WO2025008409A3 PCT/EP2024/068750 EP2024068750W WO2025008409A3 WO 2025008409 A3 WO2025008409 A3 WO 2025008409A3 EP 2024068750 W EP2024068750 W EP 2024068750W WO 2025008409 A3 WO2025008409 A3 WO 2025008409A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
diagnosis
treatment
prevention
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2024/068750
Other languages
French (fr)
Other versions
WO2025008409A2 (en
Inventor
Preeti Jha
Ulrika ROSENSTRÖM
Marika NESTOR
Christoffer Bengtsson
Ulrika Yngve
Fabio BEGNINI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2025008409A2 publication Critical patent/WO2025008409A2/en
Publication of WO2025008409A3 publication Critical patent/WO2025008409A3/en
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

The disclosure provides a compound of Formula (I), or a pharmaceutically acceptable salt thereof, a method for preparation thereof as well as use thereof in the treatment and/or diagnosis of cancer such as neuroblastoma, prostate cancer, pancreatic cancer, leukemia, osteosarcoma, hepatoblastoma, lung cancer, colon cancer, breast cancer, skin cancer, thyroid cancer and/or rhabdoid cancer.
PCT/EP2024/068750 2023-07-03 2024-07-03 Substituted 2-phenylpiperidine compounds for use in the diagnosis, treatment and/or prevention of cancer Pending WO2025008409A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE2350829-4 2023-07-03
SE2350829 2023-07-03

Publications (2)

Publication Number Publication Date
WO2025008409A2 WO2025008409A2 (en) 2025-01-09
WO2025008409A3 true WO2025008409A3 (en) 2025-02-13

Family

ID=91853842

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/068750 Pending WO2025008409A2 (en) 2023-07-03 2024-07-03 Substituted 2-phenylpiperidine compounds for use in the diagnosis, treatment and/or prevention of cancer

Country Status (1)

Country Link
WO (1) WO2025008409A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993004040A1 (en) * 1991-08-20 1993-03-04 Merck Sharp & Dohme Limited Azacyclic compounds, processes for their preparation and pharmaceutical compositions containing them

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU679207B2 (en) 1993-02-18 1997-06-26 Merck Sharp & Dohme Limited Azacyclic compounds, compositions containing them and their use as tachykinin antagonists
WO1995020575A1 (en) 1994-01-28 1995-08-03 Merck Sharp & Dohme Limited Aralkylamino substituted azacyclic therapeutic agents
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993004040A1 (en) * 1991-08-20 1993-03-04 Merck Sharp & Dohme Limited Azacyclic compounds, processes for their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
WO2025008409A2 (en) 2025-01-09

Similar Documents

Publication Publication Date Title
PH12021552482A1 (en) Compounds targeting prmt5
MX2024000299A (en) Anti-viral compounds.
TW200635923A (en) Tricyclic heterocycles, their manufacture and use as pharmaceutical agents
WO2002057261A3 (en) Diaminothiazoles and their use as inhibitors of cyclin-dependent kinase
AU2002950217A0 (en) 8- Hydroxy Quinoline Derivatives
PT1353672E (en) Synthesis of 4-amino-thalidomide enantiomers
UA83182C2 (en) Compounds effecting glucokinase
WO2009067397A3 (en) Treatment for solid tumors
NZ511938A (en) Use of AT-1 receptor antagonist or treating diseases associated with an increase of AT-1 receptor
EA200800516A1 (en) DERIVATIVES N-PHENYL-2-PYRIMIDINAMINE AND THE PROCESS OF THEIR RECEPTION
PH12021552513A1 (en) Pyrrole compounds
TNSN07294A1 (en) Treatment of metastasized tumors
WO2010002465A3 (en) Methods for treating neoplasia by inhibiting lactate dehydrogenase and/or nicotinamide phosphoribosyltransferase
MX2024003738A (en) Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds.
TW200624431A (en) Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
MXPA04004606A (en) Solubilized topoisomerase poisons.
BR112021022216A2 (en) 6-(2,4-Dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7] acid ]annulene-2-carboxylic acid for use in patients with metastatic or advanced breast cancer
PH12021552953A1 (en) Tricyclic compounds
MXPA05005790A (en) Aminoalkoxyindoles as 5-ht6-receptor ligands for the treatment of cns-disorders.
TW200531688A (en) Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents
WO2025008409A3 (en) Substituted 2-phenylpiperidine compounds for use in the diagnosis, treatment and/or prevention of cancer
WO2023039081A3 (en) Ink4 tumor suppressor proteins mediate resistance to cdk4/6 kinase inhibitors
WO2004044174A3 (en) Topoisomerase-targeting agents
BG108932A (en) Pharmaceutical composition comprising arsenite for the treatment of malignancy
WO2007092436A3 (en) Compounds for treating inflammatory disorders, demyelinating disorders and cancers

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24739519

Country of ref document: EP

Kind code of ref document: A2